EUS-RFA PANCARDINAL-1 Trial

The film gives the main points. The full list below is copied from the registry; the study team makes the final decision.

• Age18 Years to no maximum
• SexAll
• Healthy volunteersNo

You may be able to join if

• Diagnosed and histologically-confirmed PDAC by biopsy
• Permanent street address
• Consent to study participation
• Axial CT scan consistent with PDAC
• No prior chemotherapy or less than 2 months of pre-operative chemotherapy for PDAC
• Eastern Cooperative Oncology Group (ECOG) performance status of 0-2

You cannot join if

• Male or female patients < 18 years of age
• No permanent street address or telephone number
• Pregnant patients
• Inmates or prisoners
• Unable to provide informed consent

This is how the treatment is meant to work. Whether it helps, and how safe it is, is what this trial is testing.

Treatments listed in the registry

• Endoscopic Ultrasound (EUS)-Guided Radiofrequency Ablation (RFA) (Device): Endoscopic ultrasound (EUS)-guided radiofrequency ablation (RFA) consists of the application of an alternating current with a frequency of 350-500 kilohertz (kHz) to the target tissue via a special electrode located at the tip of an echoendoscope. The alternating current causes the vibratory movement of ionic particles in the abutting and adjoining tissue and results in the generation of heat. However, RFA induces not only local disruption of the tumor by heat, but it also produces localized coagulation necrosis of the tumor; which induces the release of large amounts of cellular debris. This cellular debris represents a source of tumor antigens that can trigger a host adaptive immune response against the tumor.
• Neoadjuvant Chemotherapy (NAC) (Drug): The NAC regimen will be determined clinically by the participant's physician [possible regimens are either mFOLFIRINOX or Gemcitabine Nab-Paclitaxel +/- Cisplatin (GemAbraxane)].

Na · Single Group · masking: None

As the registry describes them. Requirements to join, such as a tissue sample, are in the eligibility list above even when on-study procedures are optional. Ask the study team which steps apply to you.

• endoscopy: Part of the study plan

Main goals

• Number of participants who are able to complete neoadjuvant chemotherapy plus EUS-RFA and later undergo surgical tumor resection (From the time of EUS-RFA NAC intervention to the time of surgical tumor resection (about 5-6 months))

Other goals

• Radiographic treatment response as assessed by standard Response evaluation criteria in solid tumors (RECIST) criteria
• Radiographic treatment response as assessed by standard Response evaluation criteria in solid tumors (RECIST) criteria
• Number of participants with post-operative complications
• Disease-free survival time

Planned enrollment: 60 (estimated).

• Memorial Hermann Hospital, Houston, Texas

Site status as of Oct 30, 2026. Check the live record before contacting a site.

• ClinicalTrials.gov NCT04990609

Registry record reviewed as fetched Oct 30, 2026, last updated by the sponsor Jul 28, 2026. Public record; not medical advice.